


RETRACTION NOTE **OPEN**

Retraction Note: Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer

Xiao Tan, Zhongqiang Zhang, Ping Liu, Hongliang Yao , Liangfang Shen and Jing-Shan Tong

© The Author(s) 2023

Cell Death and Disease (2023)14:226; <https://doi.org/10.1038/s41419-023-05764-6>

Retraction to: *Cell Death and Disease* <https://doi.org/10.1038/s41419-020-03266-3>, published online 12 December 2020

The Editors-in-Chief have retracted this article at the authors' request. After publication, concerns were raised regarding image similarities between this article and a number of previously published articles, specifically:

Several images in Fig. 6D and E appear highly similar to those in Fig. 6C and D in [1], Fig. 6D and E in [2], Fig. 5E and F in [3], and Fig. 7E in [4].

Fig. 5E input appears highly similar to Fig. 4E input in [1].

The authors have stated that the images in Fig. 6 were misused and could not be reproduced, which undermined the reliability of the conclusions. The Editors-in-Chief therefore no longer have confidence in the presented data and the conclusions of the article.

All authors agree to this retraction.

REFERENCES

1. Lin L, Ding D, Jiang Y. MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells. *Oncogenesis*. 2018;7:67 <https://doi.org/10.1038/s41389-018-0078-y>.
2. Yue D, Sun X. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. *Cell Death Dis*. 2018;9:935 <https://doi.org/10.1038/s41419-018-0960-8>.
3. Yan J, Yang S, Tian H. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer. *Cell Death Dis*. 2020;11:943 <https://doi.org/10.1038/s41419-020-03154-w>.
4. Cao Y, Li X, CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. *J Cell Mol Med*. 2020;24:5135–45. <https://doi.org/10.1111/jcmm.15156>.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023